PTPN11 / SHP2 review notes

Scope and evidence policy

• Review target: human PTPN11 (UniProt Q06124), all 258 seeded GOA rows.
• The available deep-research providers were reported as globally quota-blocked, so no provider was retried and no provider-style file was created. This journal instead uses the reviewed UniProt record and locally cached primary literature.
• Experimental annotations were not rejected merely because a cached paper is abstract-only. Where the annotation is biologically coherent but represents a downstream or tissue-specific outcome, it is retained as KEEP_AS_NON_CORE; where a high-throughput localization lacks mechanistic support, it is left UNDECIDED.
• All 82 protein binding rows preserve the reported interactions but are marked MARK_AS_OVER_ANNOTATED, because GO:0005515 does not identify the biologically informative phosphotyrosine-, receptor-, or kinase-binding activity.

Core molecular mechanism

PTPN11 encodes SHP2, a non-receptor protein tyrosine phosphatase with tandem N-terminal SH2 domains, a catalytic PTP domain, and a regulatory C-terminal tail. In the basal state, the N-SH2 domain occludes the phosphatase active site; phosphotyrosine-ligand binding relieves autoinhibition and recruits the enzyme to signaling complexes. PMID:32184441 PMID:32184441

The catalytic activity is experimentally established on physiological protein substrates. Sprouty proteins are direct SHP2/Corkscrew targets, providing a mechanism by which dephosphorylating an RTK feedback inhibitor promotes RTK output. PMID:16481357 PMID:16481357 SHP2 also dephosphorylates parafibromin and thereby promotes Wnt signaling; disease-associated variants measurably alter this activity. PMID:26742426

SHP2 is therefore unusual among phosphatases in often acting positively on RAS-ERK output. Activating Noonan-syndrome substitutions increase SHP2 catalytic activity and MAPK signaling. PMID:28074573 PMID:28074573

Binding and adaptor activities

The tandem SH2 domains confer phosphotyrosine-dependent recruitment and enzyme activation. In the PD-1 system, SHP2 bridges two phosphorylated ITSM motifs and this interaction robustly activates its phosphatase activity. PMID:32184441 This supports phosphotyrosine-residue binding as a core activity while keeping PD-1/T-cell inhibition as one context-specific output.

SHP2 can also act as a molecular adaptor independently of a substrate-product relationship. It binds activated insulin receptor and promotes IRS1 recruitment and glucose uptake. PMID:7493946 In innate immunity, a Siglec1-DAP12 complex recruits SHP2 as a scaffold, which in turn recruits TRIM27 to promote TBK1 degradation. PMID:26358190 These observations support a distinct molecular-adaptor core function while the insulin and antiviral outcomes remain non-core contexts.

Developmental roles and the cerebellar module

PTPN11 is pleiotropic. Human germline variants cause Noonan syndrome and perturb the balance between inactive and active SHP2 conformations. PMID:11704759 PMID:11704759 Broad brain, craniofacial, cardiac, ear, and genital-development GO annotations are retained as non-core phenotypic/developmental consequences rather than being promoted to SHP2's defining molecular function.

For cerebellar development, conditional mouse genetics gives a cell-type-resolved role. Pan-cerebellar Ptpn11 deletion blocks radial-glia-to-Bergmann-glia transformation, disrupts lamination, and eliminates foliation, whereas GCP-lineage deletion has no phenotype. PMID:24431450 PMID:24431450 The study places SHP2 downstream of FGF8 and upstream of ERK in radial glia/nascent Bergmann glia, with active MEK1 rescue. PMID:24431450 PMID:24431450 This supports using PTPN11 as the FGF-ERK transducer for Bergmann-glia specification in a top-down cerebellar decomposition, not as a granule-cell-autonomous regulator.

Curation synthesis

• Core: non-membrane-spanning protein tyrosine phosphatase activity, peptidyl-tyrosine dephosphorylation, phosphotyrosine-residue binding/recruitment, molecular-adaptor activity, cytosolic signaling, and positive regulation of ERK output.
• Non-core but supported contexts: ERBB/EGFR/FGFR/ephrin/insulin/cytokine signaling; immune checkpoint and innate-immune regulation; adhesion/focal-adhesion outputs; vascular mechanotransduction; and developmental phenotypes.
• Unresolved: nucleolar and mitochondrial localization annotations lack enough mechanistic context in the available evidence and remain UNDECIDED.
• Over-annotated: generic protein binding, generic protein-containing complex, and generic positive regulation of intracellular signal transduction do not convey a useful SHP2 activity.